1. SWAG SSG Breast Cancer Meeting
Clinical Research Network
West of England
SWAG SSG Breast Cancer Meeting
Friday 27th January 2017
Research Report

2. Clinical Research Network & Cancer Services
West ofEngland
SWAG - Somerset Wiltsire Avon & Gloucestershire
South West Children’s Cancer & Leukaemia
Research Network

3. NIHR CRN High Level Objectives
Increase number of participants into NIHR CRN portfolio studies
650,000 in England
21,905 in West of England
Increase the number of studies that deliver to time and target
Target 80%
Increase number of commercial studies delivered through network
Reduce NHS study set up times
Reduce time taken to recruit first participant

4. NIHR CRN Objectives for cancer
Recruit 20% of cancer incidence
West of England 1,909
Recruit 7.5% of cancer incidence into interventional studies
716
Include challenging studies
Cancer surgery – 4 recruits per 100,000 population
Radiotherapy – 6 recruits per 100,000 population
Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population
Children & young people – 3 per 100,000 population
Teenagers & young adults – record number of year olds participating in research

6. *Please note the Office of National Statistics uses different regions from the NIHR so this calculation is approximate. The South West region loosely correlates to West of England and South West Peninsula CRNs, with the addition of Dorset.

8. West of England recruitment to Cancer studies per Trust

9. What does the current portfolio look like?
23 Studies
8 Acute Trusts in the SWAG region.
72% of study sites are currently meeting Recruitment to Time and Target (RTT)
POSNOC in Bath
M Phase III Veliparib/ Placebo + C/P Breast Cancer Study in University Hospitals Bristol
Breast cancer studies open in SWAG largely reflect a balanced portfolio by sub-topic, though only 1 metastatic study is open at present

10. Current portfolio balance

11. Studies in set up – Breast Cancer
Portfolio ID
Study Title
Project type
Trust
Principal Investigator
16444
CiPHER - Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases
Non-commercial
University Hospitals Bristol
Bahl, Dr Amit
19708
IBIS 3: POLaR - Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment
19754
Exercise to prevent shoulder problems (PROSPER)
30433
PARTNER - addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA
Braybrooke, Dr Jeremy
31440
CompLEEment-1 - ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer
Commercial
31608
plasmaMATCH - The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices
32994
PALLAS - Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+ / HER2 - early breast cancer

12. Current issues with breast cancer research
Clinical pressures with some trial treatments
Pharmacy capacity issues
Extra time for administration of infusions
Extra length of treatment courses
Clinic space to see patients
Affordability to the NHS of the drugs we are researching
What should our regional portfolio look like?
Should we consider the whole region population when forecasting for trials?
Should we encourage more cross referral of patients for studies?
Should we select studies that will be more useful to the NHS?

13. Useful links https://www.crn.nihr.ac.uk/
National and local network information including training programmes templates, tools, contacts, videos etc
Open data platform. Look at performance across whole CRN including all specialty areas
/csg.ncri.org.uk/portfolio/portfolio-maps/
View current national portfolio of open, closed and ‘in set up’ cancer studies
See where a study is open across the country
Search for a study to fit criteria. Good for horizon scanning, eligibility criteria

14. Contacts Research Delivery Manager – maxine.taylor@nihr.ac.uk
Cancer portfolio facilitator –
Breast cancer research lead –